Andreassen Lab

Publications

Hater, N; Iwaniuk, KM; Leifeld, C; Grüten, P; Wiek, C; Raba, K; Zhang, F; Fischer, JC; Andreassen, PR; Hanenberg, H; et al. Identification of new RAD51D-regulating microRNAs that also emerge as potent inhibitors of the Fanconi anemia/homologous recombination pathways. Human Molecular Genetics. 2022; 31:4241-4254.

Abe, H; Yeh, YH; Munakata, Y; Ishiguro, KI; Andreassen, PR; Namekawa, SH. Active DNA damage response signaling initiates and maintains meiotic sex chromosome inactivation. Nature Communications. 2022; 13:7212.

Chihanga, T; Vicente-Muñoz, S; Ruiz-Torres, S; Pal, B; Sertorio, M; Andreassen, PR; Khoury, R; Mehta, P; Davies, SM; Lane, AN; et al. Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. Cancers. 2022; 14:2040.

Alavattam, KG; Maezawa, S; Andreassen, PR; Namekawa, SH. Meiotic sex chromosome inactivation and the XY body: a phase separation hypothesis. Cellular and Molecular Life Sciences. 2022; 79:18.

Abe, H; Meduri, R; Li, Z; Andreassen, PR; Namekawa, SH. RNF8 is not required for histone-to-protamine exchange in spermiogenesis†. Biology of Reproduction. 2021; 105:1154-1159.

Andreassen, PR; Seo, J; Wiek, C; Hanenberg, H. Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses. Genes. 2021; 12:1034.

Zhang, Y; Park, JY; Zhang, F; Olson, SH; Orlow, I; Li, Y; Kurtz, RC; Ladanyi, M; Chen, J; Toland, AE; et al. The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response. Human Mutation. 2021; 42:150-163.

Abe, H; Alavattam, KG; Hu, Y; Pang, Q; Andreassen, PR; Hegde, RS; Namekawa, SH. The Initiation of Meiotic Sex Chromosome Inactivation Sequesters DNA Damage Signaling from Autosomes in Mouse Spermatogenesis. Current Biology. 2020; 30:408-420.e5.

Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.

Jayavaradhan, R; Pillis, DM; Goodman, M; Zhang, F; Zhang, Y; Andreassen, PR; Malik, P. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Nature Communications. 2019; 10:2866.

Hanenberg, H; Andreassen, PR. PALB2 (partner and localizer of BRCA2). Atlas of genetics and cytogenetics in oncology and haematology. 2018; 22:484-490.

Toland, AE; Andreassen, PR. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment. Journal of medical genetics. 2017; 54:721-731.

Alavattam, KG; Kato, Y; Sin, H; Maezawa, S; Kowalski, IJ; Zhang, F; Pang, Q; Andreassen, PR; Namekawa, SH. Elucidation of the Fanconi Anemia Protein Network in Meiosis and Its Function in the Regulation of Histone Modifications. Cell Reports. 2016; 17:1141-1157.

Park, J; Virts, EL; Jankowska, A; Wiek, C; Othman, M; Chakraborty, SC; Vance, GH; Alkuraya, FS; Hanenberg, H; Andreassen, PR. Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. Journal of medical genetics. 2016; 53:672-680.

Luo, Z; Xin, D; Liao, Y; Berry, K; Ogurek, S; Zhang, F; Zhang, L; Zhao, C; Rao, R; Dong, X; et al. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. Nature Communications. 2023; 14:762.

Hashimoto, M; Li, J; Andreassen, PR; Huang, G. CPT1a Controls the Function of Long-Term Hematopoietic Stem Cells By Regulating the Balance between Fatty Acid Oxidation and Oxphos in Mitochondria. Blood. 2023; 142:4089.

Radulovic, I; Schündeln, MM; Müller, L; Ptok, J; Honisch, E; Niederacher, D; Wiek, C; Scheckenbach, K; Leblanc, T; Larcher, L; et al. A novel cancer risk prediction score for the natural course of FA patients with biallelic BRCA2/FANCD1 mutations. Human Molecular Genetics. 2023; 32:1836-1849.

Hater, N; Iwaniuk, KM; Leifeld, C; Grüten, P; Wiek, C; Raba, K; Zhang, F; Fischer, JC; Andreassen, PR; Hanenberg, H; et al. Identification of new RAD51D-regulating microRNAs that also emerge as potent inhibitors of the Fanconi anemia/homologous recombination pathways. Human Molecular Genetics. 2022; 31:4241-4254.

Abe, H; Yeh, YH; Munakata, Y; Ishiguro, KI; Andreassen, PR; Namekawa, SH. Active DNA damage response signaling initiates and maintains meiotic sex chromosome inactivation. Nature Communications. 2022; 13:7212.

Chihanga, T; Vicente-Muñoz, S; Ruiz-Torres, S; Pal, B; Sertorio, M; Andreassen, PR; Khoury, R; Mehta, P; Davies, SM; Lane, AN; et al. Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. Cancers. 2022; 14:2040.

Alavattam, KG; Maezawa, S; Andreassen, PR; Namekawa, SH. Meiotic sex chromosome inactivation and the XY body: a phase separation hypothesis. Cellular and Molecular Life Sciences. 2022; 79:18.

Abe, H; Meduri, R; Li, Z; Andreassen, PR; Namekawa, SH. RNF8 is not required for histone-to-protamine exchange in spermiogenesis†. Biology of Reproduction. 2021; 105:1154-1159.

Andreassen, PR; Seo, J; Wiek, C; Hanenberg, H. Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses. Genes. 2021; 12:1034.

Zhang, Y; Park, JY; Zhang, F; Olson, SH; Orlow, I; Li, Y; Kurtz, RC; Ladanyi, M; Chen, J; Toland, AE; et al. The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response. Human Mutation. 2021; 42:150-163.

Abe, H; Alavattam, KG; Hu, Y; Pang, Q; Andreassen, PR; Hegde, RS; Namekawa, SH. The Initiation of Meiotic Sex Chromosome Inactivation Sequesters DNA Damage Signaling from Autosomes in Mouse Spermatogenesis. Current Biology. 2020; 30:408-420.e5.

Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.

Jayavaradhan, R; Pillis, DM; Goodman, M; Zhang, F; Zhang, Y; Andreassen, PR; Malik, P. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Nature Communications. 2019; 10:2866.

Dong, Y; Zhao, X; Feng, X; Zhou, Y; Yan, X; Zhang, Y; Bu, J; Zhan, D; Hayashi, Y; Zhang, Y; et al. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Leukemia. 2019; 33:2585-2598.

Ge, C; Vilfranc, CL; Che, L; Pandita, RK; Hambarde, S; Andreassen, PR; Niu, L; Olowokure, O; Shah, S; Waltz, SE; et al. The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development. Hepatology. 2019; 69:2608-2622.

Lewis, TW; Barthelemy, JR; Virts, EL; Kennedy, FM; Gadgil, RY; Wiek, C; Linka, RM; Zhang, F; Andreassen, PR; Hanenberg, H; et al. Deficiency of the Fanconi anemia E2 ubiqitin conjugase UBE2T only partially abrogates Alu-mediated recombination in a new model of homology dependent recombination. Nucleic Acids Research. 2019; 47:3503-3520.

Willoughby, A; Andreassen, PR; Toland, AE. Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy. Journal of Personalized Medicine. 2019; 9:E16.

Willoughby, A; Andreassen, PR; Toland, AE. Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer. Journal of Personalized Medicine. 2019; 9:E15.